Fasenra (benralizumab) / AstraZeneca, Kyowa Kirin - LARVOL DELTA

Fasenra, Nucala equally effective, safe in EGPA: Real-world study (ANCA Vasculitis News) - P=NA | N=176 | "The results showed that after three months of treatment, complete or partial responses were achieved by a similar proportion of patients treated with Nucala or Fasenra (45.4% vs. 51.1%). The number of patients achieving a complete response increased over time with both medications. However, after one year, the complete response rate was significantly higher in the Fasenra group than among those on Nucala (48.1% vs. 32.4%)...After achieving complete response, five Nucala-treated patients and four Fasenra-treated patients relapsed, the data showed...In terms of safety, there were no significant group differences in the proportions of patients who discontinued treatment — 10% with Nucala and 18% with Fasenra — and who reported adverse events, as done by 12.5% on Nucala and 18% on Fasnra."

Real-world • Eosinophilic Granulomatosis With Polyangiitis

Systematic review of measured biomarker changes after biologic treatments for CRSwNP (COSM 2025) - " Of 51 included studies, breakdown by biologic was: Dupilumab- 26, Omalizumab- 8, Mepolizumab- 6, Benralizumab- 8, Resilizumab-1, and other-2. Current literature studying biologics in CRSwNP have predominantly focused on only a select few biomarkers known to be key mediators of type 2 inflammation. Systemic top 3- IgE (19), Eosinophils (37) and ECP (8). Nasal top 3- Eosinophils (10), IgE (7), ECP (7)."

Biomarker • Review • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilia • Inflammation

Efficacy of Biologic Agents in Management of Pediatric Asthma (PAS 2025) - "Control of severe asthma has always been a challenge, and the advent of biologic therapy (omalizumab, mepolizumab, dupilumab, benralizumab, and tezepelumab) has revolutionized the treatment of this category of asthma. These factors will also be assessed for the year following initiation for evaluation of outcomes. Outcomes pre and post-biologic initiation will be compared using dependent sample t-testing, conducted with IBM SPSS."

Clinical • Asthma • Immunology • Pediatrics • Respiratory Diseases • IL4 • IL5 • TSLP

Exploring a novel approach to COPD treatment: benralizumab effect in an ex vivo 3-D model. (PubMed, Respir Med) - "The findings described lead to speculate on a potential action of benralizumab on alternative inflammatory targets."

Journal • Preclinical • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL15 • IL6

Blue Cross Blue Shield now requires prior approval for severe asthma drugs in some states (Yahoo News) - "Patients in five states who have severe asthma and are covered by Blue Cross Blue Shield are facing a new obstacle to getting treatment...On Tuesday, BCBS began mandating that severe asthma patients self-administer their drugs at home, unless their provider gets prior approval from the insurance company....The patients affected are those covered in Illinois, Texas, Oklahoma, New Mexico, and Montana, but not those with Medicare or Medicaid, the insurance giant says. Those five states are included in a combined BCBS plan which is owned by Health Care Service Corporation...Given as injections, the treatments in question are Fasenra (benralizumab), Tezspire (tezepelumab), Nucala (mepolizumab) and Xolair (omalizumab). All belong to a class of drugs known as biologics."

Commercial • Asthma • Immunology

Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma. (PubMed, Allergy) - No abstract available

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Comparative effectiveness of dupilumab versus mepolizumab and benralizumab in asthma: a multinational retrospective cohort study. (PubMed, J Allergy Clin Immunol Pract) - "Dupilumab was associated with a decreased risk of asthma exacerbations compared to both mepolizumab and benralizumab among patients with asthma. Further research incorporating comprehensive biomarker data is needed to optimize biologic selection."

HEOR • Journal • Retrospective data • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Effectiveness of tezepelumab in preventing relapse of eosinophilic granulomatosis with polyangiitis: A case report. (PubMed, Respir Investig) - "A 54-year-old woman diagnosed with eosinophilic granulomatosis accompanied by polyangiitis (EGPA) was in remission with prednisolone (PSL) and mepolizumab treatment. Consequently, the treatment with benralizumab was changed to tezepelumab, after which her symptoms immediately improved and her ANCA levels decreased, enabling reduction in the PSL dosage. This case highlights the potential of tezepelumab to reduce ANCA levels in EGPA-related severe asthma."

Journal • Asthma • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Langerhans Cell Histiocytosis • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Vasculitis

Comparison of clinical outcomes with Benralizumab in severe eosinophilic asthma: Switched and naïve patients (EAACI 2025) - No abstract available

Clinical • Clinical data • Late-breaking abstract • Immunology

Effects of benralizumab on T cell adhesion molecules in severe eosinophilic asthma: modulation by IL-25 and IL-33 (EAACI 2025) - No abstract available

Late-breaking abstract • Immunology • IL33

Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab (EAACI 2025) - No abstract available

Biomarker • Clinical • Late-breaking abstract • Immunology

Benralizumab reduces annual cumulative OCS dose while improving asthma control and quality of life in severe eosinophilic asthma: Real-World Evidence from the AURORA study (EAACI 2025) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Immunology

Overcoming DRESS Syndrome with HLH and Organ Failure: The Potential Role of Benralizumab (EAACI 2025) - No abstract available

Immunology

Lymphocyte profile and asthma control during the treatment with benralizumab in real life (EAACI 2025) - No abstract available

Clinical • Immunology

A Case of Herpes Zoster Following the First Dose of Benralizumab (EAACI 2025) - No abstract available

Clinical • Immunology

Inhaled Corticosteroid Reduction Effects on Asthma Outcomes after Three Years of Benralizumab Treatment in Severe Asthma Patients (EAACI 2025) - No abstract available

Clinical • Immunology

A Novel Treatment for Drug-Induced Acute Interstitial Nephritis: Benralizumab (EAACI 2025) - No abstract available

Immunology

The treatment of eosinophilic asthma with mepolizumab and benralizumab: relative effectiveness (EAACI 2025) - No abstract available

Immunology

ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up (EAACI 2025) - No abstract available

Clinical • Immunology

Efficacy of Benralizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) in a Real-World Setting: Experience at La Paz University Hospital (EAACI 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Vasculitis

Benralizumab as treatment in a patient with Near-Fatal Asthma exacerbation (EAACI 2025) - No abstract available

Clinical • Immunology

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma (clinicaltrials.gov) - P3 | N=476 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2026 ➔ Mar 2026

Enrollment closed • Trial completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Treatment of allergic bronchopulmonary aspergillosis with biologics. (PubMed, Chin Med J Pulm Crit Care Med) - "Data on dupilumab and tezepelumab are limited; however, they may be effective in patients who are resistant to treatment with omalizumab/mepolizumab/benralizumab. Future studies examining the effects of these biologics in preventing the recurrences/exacerbations of ABPA are warranted."

Journal • Review • Allergic Bronchopulmonary Aspergillosis • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Utility of the Basophil Reactivity Test in the Clinical Management of People with Severe Uncontrolled Asthma. (PubMed, J Asthma Allergy) - "The BAT was associated with poor response above the cut-off values of 10.5% for mepolizumab, 15.5% for omalizumab, and 28% for benralizumab. Patients with basophil reactivity greater than or equal to 29% were less likely to achieve full control of asthma when treated with omalizumab, mepolizumab, or benralizumab, independently of classic clinical or biological markers of type 2 asthma."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Real-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry. (PubMed, J Clin Med) - "Three patients (3.8%) were treated with omalizumab, 23 patients (28.8%) with mepolizumab, 33 patients (41.2%) with benralizumab and 21 patients (26.2%) with tezepelumab. No treatment-related adverse events were noticed. The administration of current biologic agents in patients with severe asthma seems to be both effective and safe, sparing the toxicity of oral corticosteroids."

HEOR • Journal • Real-world evidence • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases